02.05.20

Staar Surgical Announces Strategic Cooperation Agreement with Senshinkai Eye Institute in Japan

Source: Staar Surgical

Staar Surgical announced that it entered a strategic cooperation agreement with Senshinkai Eye Institute (SEI), an eye care group with five locations in Japan. The agreement includes volume commitments for the company’s implantable collamer lenses (ICLs), ICL surgeon training and certification, tools for patient education and co-marketing.

Financial terms of the deal were not disclosed.

“In Japan and globally, the significant increase in the myopic population1 is a megatrend that compromises human quality of life (QOL) while contributing to socio-economic losses. In my opinion, we as ophthalmological pioneers must actively work on a safe and long-term treatment of myopia,” Yoshitaka Oka, MD, and Chairman of Senshinkai Eye Institute, said in a company news release. “Staar Surgical’s EVO ICL can provide patients with improved visual quality using a unique and proprietary material with proven long-term stability and safety. I have been performing ICL surgery since 2010 and have always believed that ophthalmic care must consider QOL and an optimal and customized treatment for patients. The EVO ICL family of lenses is an indispensable partner in achieving these goals and my treatment of myopia.”

Senshinkai Eye Institute personnel totals 115, including 12 full-time and 20 part-time medical doctors and 17 specialist optometrists across five locations in the Tokyo, Osaka, and Fukuoka prefectures.

“We are excited to partner and support Dr. Oka and the Senshinkai Eye Institute through this new strategic cooperation agreement,” Caren Mason, President and CEO of Staar Surgical, said in the news release. “Japan is a very important market for Staar, where, similar to the United States, the number of laser vision correction procedures has declined significantly while the need for vision correction remains high. SEI operates the second largest number of refractive surgery clinics in Japan. Our goal with SEI and our EVO ICL family of lenses is to offer as many suitable patients as possible the opportunity for a lifestyle of visual freedom without the hassles and costs associated with eyeglasses and disposable contact lenses.”

1 Holden at al. (2016), “Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050”, Ophthalmology, Volume 124, Issue 5, pp 1036-1042

Related Content